Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric).
M. Khasraw
Research Funding - Merck Serono
S. A. McCowatt
Research Funding - Merck KGaA
Z. Kerestes
No relevant relationships to disclose
M. E. Buyse
No relevant relationships to disclose
M. Back
Honoraria - Schering-Plough
H. Wheeler
Research Funding - Merck Serono
Expert Testimony - Merck Serono